ArticleInternational journal of molecular sciences2018

Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.

Rosario Di Maggio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.